Discover drugs with Deep Physics and AI
What we do
Aqemia is a deep-tech start-up in drug discovery. Our ambition is to discover better and more innovative therapeutic molecules faster. Better molecules because our physics-based technology has unparalleled precision. More innovative molecules because we don’t rely on past data, we’re not stuck to staying close to what already exists. Faster because our precision implies less experiments.
Aqemia leverages a unique technology based on 8 years of research in quantum and statistical mechanics at Oxford (UK), Cambridge (UK) and École normale supérieure (Paris). Our algorithms are able to compute the affinity between molecules as precisely as experiment and 10 000x faster than competition. This technology guides our AI towards the molecule that has maximum affinity for the therapeutic target yet validates other biological and physico-chemical properties.
Aqemia’s proprietary technology is licensed by an academic consortium led by Paris Sciences et Lettres (PSL) University.
We are a mix of Science and Business, and we love solving difficult problems on topics that matter.
CEO & CTO
I have worked as a Researcher for the past 9 years at ENS, CEA Saclay, Cambridge, Oxford, CNRS.
I specialize in statistical mechanics and artificial intelligence. I developed Aqemia core technology with my research team.
I love science, gifs and complicated stories made simple.
I have worked as a strategy consultant at BCG in the past 9 years.
I designed and executed projects with my teams for Pharma and B2B software company leaders.
I love discovering new topics and people, diving and bringing impact through science.